Improved web-based calculators for predicting breast carcinoma outcomes

We describe a set of web-based calculators, available at http://www.CancerMath.net, which estimate the risk of breast carcinoma death, the reduction in life expectancy, and the impact of various adjuvant treatment choices. The published SNAP method of the binary biological model of cancer metastasis uses information on tumor size, nodal status, and other prognostic factors to accurately estimate of breast cancer lethality at 15 years after diagnosis. By combining these 15-year lethality estimates with data on the breast cancer hazard function, breast cancer lethality can be estimated at each of the 15 years after diagnosis. A web-based calculator was then created to visualize the estimated lethality with and without a range of adjuvant therapy options at any of the 15 years after diagnosis, and enable conditional survival calculations. NIH population data was used to estimate non-breast-cancer chance of death. The accuracy of the calculators was tested against two large breast carcinoma datasets: 7,907 patients seen at two academic hospitals and 362,491 patients from the SEER national dataset. The calculators were found to be highly accurate and specific, as seen by their capacity for stratifying patients into groups differing by as little as a 2% risk of death, and accurately accounting for nodal status, histology, grade, age, and hormone receptor status. Our breast carcinoma calculators provide accurate and useful estimates of the risk of death, which can aid in analysis of the various adjuvant therapy options available to each patient.

[1]  Karen A Gelmon,et al.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Kevin Hughes,et al.  Predicting the survival of patients with breast carcinoma using tumor size , 2002, Cancer.

[3]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[4]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[5]  Barbara L. Smith,et al.  Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death , 2009, Cancer.

[6]  Haesook T. Kim Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[7]  Early Breast Cancer Trialists' Collaborative Group Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials , 2008, The Lancet.

[8]  Mikael Lundin,et al.  A web-based system for individualised survival estimation in breast cancer , 2003, BMJ : British Medical Journal.

[9]  S. Singletary,et al.  Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual , 2006, CA: a cancer journal for clinicians.

[10]  W. Al-Delaimy,et al.  A hospital-based retrospective cohort study of allergen immunotherapy as a preventive treatment for new onset asthma , 2005 .

[11]  E. Feuer,et al.  Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. , 2002, Journal of the National Cancer Institute.

[12]  Barbara L. Smith,et al.  Mammographic screening: Patterns of use and estimated impact on breast carcinoma survival , 2004, Cancer.

[13]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  R. Gray,et al.  Efficacy of radiotherapy for ovarian ablation , 2004, Cancer.

[15]  D J Ferguson,et al.  Dormancy of mammary carcinoma after mastectomy. , 1999, Journal of the National Cancer Institute.

[16]  D B Kopans,et al.  Breast cancer: computer simulation method for estimating optimal intervals for screening. , 1999, Radiology.

[17]  S. Mook,et al.  Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. , 2009, The Lancet. Oncology.

[18]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[19]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Michaelson Mammographic Screening: Impact on Survival , 2008 .

[21]  James S. Michaelson Using Information on Breast Cancer Growth, Spread, and Detectability to Find the Most Effective Ways for Screening to Reduce Breast Cancer Death , 2001 .

[22]  Karen R. Sepucha,et al.  Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Barbara L. Smith,et al.  The non-breast-cancer death rate among breast cancer patients , 2011, Breast Cancer Research and Treatment.

[24]  Catherine Legrand 1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[25]  Melania Pintilie,et al.  Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[26]  R. Peto,et al.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.

[27]  Barbara L. Smith,et al.  The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death , 2009, Cancer.

[28]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[29]  Donald A. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .

[30]  Gary J Whitman,et al.  Breast cancer staging. , 2006, Seminars in roentgenology.